Literature DB >> 15975300

Clinical observation of the effect of Xuesaitong soft capsule on post-hepatitis fibrosis.

Yin-quan Deng1, Xiao-fen Fan, You-di Li.   

Abstract

OBJECTIVE: To study the effect of Xuesaitong soft capsule (XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis.
METHODS: Sixty-four patients with such fibrosis were randomly divided into the treated group and control group. They were treated with XST and Dahuang Zhechong pill (NFDA1) for 3 months respectively. Their liver fibrosis criteria were examined before and after treatment.
RESULTS: The levels of serum procollagen III, hyaluronic acid, collagen IV, laminin in the two groups were significantly lower (P < 0.01) than those before treatment. The differences between the two groups were insignificant (P > 0.05).
CONCLUSION: XST could recover liver dysfunction and had anti-liver fibrosis function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975300     DOI: 10.1007/BF02835741

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  2 in total

1.  [The relationship between the levels of serum fibrosis marks and morphometric quantitative measurement of hepatic histological fibrosis].

Authors:  S Xie; J Yao; S Zheng; C Yao; R Zheng
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2000-08

2.  [Effect of Radix notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome].

Authors:  Jie Wang; Jun Xu; Jin-bai Zhong
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2004-04
  2 in total
  1 in total

1.  A network study of chinese medicine xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway.

Authors:  Linli Wang; Zheng Li; Xiaoping Zhao; Wei Liu; Yufeng Liu; Jihong Yang; Xiang Li; Xiaohui Fan; Yiyu Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-24       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.